IgA Nephropathy - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

IgA Nephropathy Market Outlook

Thelansis's "IgA Nephropathy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential IgA Nephropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

IgA Nephropathy Overview

IgA nephropathy (IgAN) is the most prevalent form of primary glomerulonephritis worldwide and is characterized by immune complex deposition in the kidneys, leading to progressive renal damage. The disease is driven by abnormal glycosylation of O-linked glycans in the hinge region of IgA1, resulting in elevated levels of galactose-deficient IgA1 (Gd-IgA1) in circulation. These abnormal IgA1 molecules are recognized by glycan-specific IgA and IgG autoantibodies, forming immune complexes that deposit in the glomeruli and trigger inflammation.

IgA, a key antibody in mucosal immunity, exists primarily as IgA1 and IgA2, with secretory IgA produced by mucosal-associated lymphoid tissues in polymeric form. In IgAN, this immune dysregulation leads to sustained kidney injury.

Clinically, IgAN follows a slow but progressive course, with approximately 30-40% of patients progressing to end-stage renal disease (ESRD) within 20-30 years. The disease may occur as sporadic (90-95%) or familial (5-10%) forms, with familial cases often associated with a more severe prognosis and faster progression to renal failure.

Key Highlights

• IgAN is a chronic, progressive renal disease with significant long-term ESRD risk
• France kidney biopsy cases expected to grow modestly from 1.5K to 1.57K (0.4% CAGR)

Market Overview

• Germany market projected to grow from $116M to $950M (>20% CAGR)
• Growth driven by emerging targeted therapies addressing underlying disease mechanisms, beyond supportive care

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Keymed Biosciences Co.Ltd
• Novartis Pharmaceuticals
• Biohaven Therapeutics Ltd.
• Jiangsu HengRui Medicine Co., Ltd.
• RemeGen Co., Ltd.
• Chengdu Suncadia Medicine Co., Ltd.
• Guangdong Hengrui Pharmaceutical Co., Ltd
• Beijing Mabworks Biotech Co., Ltd.
• Calliditas Therapeutics AB
• Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
• Biocity Biopharmaceutics Co., Ltd.
• HI-Bio, A Biogen Company
• Purespring Therapeutics Limited
• Vera Therapeutics, Inc.
• Visterra, Inc.
• Otsuka Pharmaceutical Development & Commercialization, Inc.
• Alpine Immune Sciences Inc, A Subsidiary of Vertex
• Biogen
• Sinocelltech Ltd.
• Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Travere Therapeutics, Inc.
• Arrowhead Pharmaceuticals
• Haisco Pharmaceutical Group Co., Ltd.
• Suzhou Sanegene Bio Inc.
• ADARx Pharmaceuticals, Inc.
• Apellis Pharmaceuticals, Inc.
• Alexion Pharmaceuticals, Inc.
• Amgen